MS Cannabis Therapy Developer MMJ Seeks Patent for Product …

MMJ International Holdings is seeking a patent for a part-cannabinoid and part-non-cannabinoid treatment for multiple sclerosis and other diseases.

The company said in a news release that it filed the patent request ahead of Phase 2 clinical trials of the formulation.  The therapy was developed by MMJ Bioscience, an affiliate of MMJ International Holdings, which is based in Reston, Virginia.

Dr. Bianca Weinstock-Guttman, a neurology professor at the New York State MS Consortium, will oversee the study of the potential therapy’s ability to help patients with progressive MS, the most severe form.

“Entering Phase 2 trials is a highly significant point in the development of our cannabis-based medicines,” MMJ spokesman Michael Sharpe said in the November 2017 announcement. “These trials will allow us to demonstrate efficacy in a limited number of subjects and to establish the necessary dosage regimen and delivery mechanisms to provide the most effective relief to sufferers

... read more at: https://multiplesclerosisnewstoday.com/2018/01/08/mmj-seeks-patent-on-ms-therapy-with-cannabinoid-and-non-cannabinoid-components/

by

Leave a Reply

Your email address will not be published. Required fields are marked *